Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Pharyngeal Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1PRETEXT I Hepatoblastoma 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Mouth Neoplasms 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Erdheim-Chester Disease 1Endometrial Adenocarcinoma 1Endocrine Gland Neoplasms 1Colonic Neoplasms 1Castleman Disease 1

Interventions

temsirolimus 1ixabepilone 1Vorinostat 1Taxes 1Sirolimus 1Paclitaxel 1Irinotecan 1Erlotinib Hydrochloride 1Epothilones 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adult Solid Neoplasm × temsirolimus × 90 days × Clear all
NCT01375829 2026-04-13

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
22 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡